(Q34984098)

5 August 2017

1 reference

title

Role of liver biopsy in management of chronic hepatitis C: a systematic review (English)

1 reference

5 August 2017

1 reference

1 reference

1 reference

8

Mark Sulkowski

1 reference

5 August 2017

3

Michael S Torbenson

1 reference

5 August 2017

9

Eric B Bass

1 reference

5 August 2017

1

Kelly A Gebo

1 reference

5 August 2017

H Franklin Herlong

2

1 reference

5 August 2017

Mollie W Jenckes

4

1 reference

5 August 2017

Geetanjali Chander

5

1 reference

5 August 2017

Khalil G Ghanem

6

1 reference

5 August 2017

Samer S El-Kamary

7

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 November 2002

1 reference

5 August 2017

1 reference

5 August 2017

volume

36

1 reference

5 August 2017

issue

5 Suppl 1

1 reference

5 August 2017

page(s)

S161-72

1 reference

The role of liver biopsy in hepatitis C.

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36989

Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36989

Liver biopsy in the mid-1990s: questions and answers

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36989

Pharmacological treatment of alcohol dependence: a review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36989

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36989

Efficacy of a short-term ribavirin plus interferon alpha combination therapy followed by interferon alpha alone in previously untreated patients with chronic hepatitis C: a randomized multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36989

Efficacy of 5 MU of interferon in combination with ribavirin for naïve patients with chronic hepatitis C virus: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36989

The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36989

A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C not responding to interferon alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36989

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36989

Peginterferon alfa-2a in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36989

Long-term administration of natural interferon-alpha in patients with chronic hepatitis C: relationship to serum RNA concentration, HCV-RNA genotypes, histological changes and hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36989

Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc)

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36989

Unfavourable effects of colchicine in combination with interferon-alpha in the treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36989

Chronic infection with hepatitis C virus in patients with elevated or persistently normal serum alanine aminotransferase levels: comparison of hepatic histology and response to interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36989

Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon alpha-2b for chronic hepatitis type C. Results of a multicenter randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36989

Soluble adhesion molecules correlate with liver inflammation and fibrosis in chronic hepatitis C treated with interferon-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36989

Treatment of chronic hepatitis C in patients who failed interferon monotherapy: effects of higher doses of interferon and ribavirin combination therapy. The Virginia Cooperative Hepatitis Treatment Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36989

Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36989

A randomized trial of amantadine and interferon versus interferon alone as initial treatment for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36989

Alpha but not beta interferon is useful in chronic active hepatitis due to hepatitis C virus. A prospective, double-blind, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36989

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36989

Assessment and treatment of liver disease in Japanese haemophilia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36989

Serum pro-collagen III peptide levels are related to lobular necrosis in untreated patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36989

Distinction between chronic hepatitis and liver cirrhosis in patients with hepatitis C virus infection. Practical discriminant function using common laboratory data

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36989

Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. Relationship to interferon response

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36989

Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus Interferon Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36989

Diagnostic value of serum markers of connective tissue turnover for predicting histological staging and grading in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36989

Non-invasive assessment of inflammatory activity and fibrosis (grade and stage) in chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36989

Serum hyaluronic acid is a useful marker of liver fibrosis in chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36989

Serum hyaluronic acid reflects the effect of interferon treatment on hepatic fibrosis in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36989

Serum hyaluronan as a marker of liver fibrosis in hemophiliacs with hepatitis C virus-associated chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36989

Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36989

Aspartate aminotransferase: alanine aminotransferase ratio in chronic hepatitis C infection: is it a useful predictor of cirrhosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36989

AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36989

Serum HCV RNA titer does not predict the severity of liver damage in HCV carriers with normal aminotransferase levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36989

Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. METAVIR and CLINIVIR Cooperative Study Groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36989

Correlation of viral RNA, alanine aminotransferase, and histopathology in hepatitis C virus-associated hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36989

Serum alpha-fetoprotein levels in patients with chronic hepatitis C. Relationships with serum alanine aminotransferase values, histologic activity index, and hepatocyte MIB-1 scores

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36989

Relationships between serum aminotransferase levels, liver histologies and virological status in patients with chronic hepatitis C in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36989

Stability of HCV-RNA level and its lack of correlation with disease severity in asymptomatic chronic hepatitis C virus carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36989

Correlation of soluble interleukin-2 receptor levels with severity of chronic hepatitis C virus liver injury and development of hepatocellular cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36989

Serum total bile acid level as a sensitive indicator of hepatic histological improvement in chronic hepatitis C patients responding to interferon treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36989

21 January 2018

Identifiers

DOI

10.1053/JHEP.2002.36989

1 reference

5 August 2017

1 reference